Forty Seven, Inc.

( )
FTSV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 8.01%133.020.7%$2089.11m
PFEPfizer Inc. 5.73%32.670.9%$1513.86m
MRKMerck & Co., Inc. 7.36%77.010.7%$1388.76m
ABBVAbbVie, Inc. 3.47%75.192.3%$1255.20m
BMYBristol-Myers Squibb Co. 3.05%54.401.0%$1095.12m
LLYEli Lilly & Co. 3.19%138.391.1%$925.01m
FTSVForty Seven, Inc. 0.87%95.370.0%$327.47m
NVSNovartis AG 3.28%81.880.2%$324.18m
GSKGlaxoSmithKline Plc 3.21%37.610.2%$285.52m
AZNAstraZeneca Plc 4.85%44.531.2%$281.34m
NVONovo Nordisk A/S 6.08%60.180.1%$176.98m
SNYSanofi 5.30%44.690.2%$166.73m
BHCBausch Health Cos., Inc. 5.10%15.250.0%$109.46m
RGENRepligen Corp. 3.53%95.827.1%$75.04m
RETAReata Pharmaceuticals, Inc. 7.93%161.883.4%$72.88m

Company Profile

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.